Affimed NV (NASDAQ: AFMD) Q2 2021 earnings call dated Sep. 08, 2021 Corporate Participants: Alexander Fudukidis -- Head of Investor Relations Adi
Affimed NV
-(AFMD)
XNAS:AFMD
Affimed N.V. (AFMD) Q3 2020 Earnings Call Transcript
Affimed N.V. (NASDAQ: AFMD) Q3 2020 earnings call dated Nov. 10, 2020 Corporate Participants: Alexander Fudukidis -- Head of Investor Relations Adi Hoess -- Chief Executive
Affimed N.V. (NASDAQ: AFMD) Q1 2020 Earnings Call Transcript
Affimed N.V. (AFMD) Q1 2020 earnings call dated Jun. 23, 2020 Corporate Participants: Alexander Fudukidis -- Head of Investor Relations Adi Hoess -- Chief Executive Officer
Affimed (AFMD): Q3 2019 Earnings Snapshot
-- Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year. -- Revenues were EUR2.1
Affimed’s stock tanks as company announces termination of cancer program
Affimed NV (NASDAQ: AFMD) reported first-quarter 2019 earnings results and announced its plans to terminate its cancer program while focusing its R&D
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped